Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies.

Hdl Handle:
http://hdl.handle.net/10147/135050
Title:
Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies.
Authors:
Quigley, Eamonn M M
Affiliation:
Department of Medicine, Alimentary Pharmabiotic Centre, Cork University Hospital, University College Cork, Clinical Sciences Building, Cork, Ireland. e.quigley@ucc.ie
Citation:
Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. 2011, 40 (1):207-22 Gastroenterol. Clin. North Am.
Journal:
Gastroenterology clinics of North America
Issue Date:
Mar-2011
URI:
http://hdl.handle.net/10147/135050
DOI:
10.1016/j.gtc.2010.12.009
PubMed ID:
21333908
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21333908
Abstract:
Several recent observations have raised the possibility that disturbances in the gut microbiota and/or a low-grade inflammatory state may contribute to symptomatology and the etiology of irritable bowel syndrome (IBS). Consequent on these hypotheses, several therapeutic categories have found their way into the armamentarium of those who care for IBS sufferers. These agents include probiotics, prebiotics, antibiotics, and anti-inflammatory agents.
Item Type:
Article
Language:
en
MeSH:
Anti-Bacterial Agents; Anti-Inflammatory Agents; Humans; Irritable Bowel Syndrome; Prebiotics; Probiotics; Synbiotics
ISSN:
1558-1942

Full metadata record

DC FieldValue Language
dc.contributor.authorQuigley, Eamonn M Men
dc.date.accessioned2011-07-01T10:23:36Z-
dc.date.available2011-07-01T10:23:36Z-
dc.date.issued2011-03-
dc.identifier.citationTherapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. 2011, 40 (1):207-22 Gastroenterol. Clin. North Am.en
dc.identifier.issn1558-1942-
dc.identifier.pmid21333908-
dc.identifier.doi10.1016/j.gtc.2010.12.009-
dc.identifier.urihttp://hdl.handle.net/10147/135050-
dc.description.abstractSeveral recent observations have raised the possibility that disturbances in the gut microbiota and/or a low-grade inflammatory state may contribute to symptomatology and the etiology of irritable bowel syndrome (IBS). Consequent on these hypotheses, several therapeutic categories have found their way into the armamentarium of those who care for IBS sufferers. These agents include probiotics, prebiotics, antibiotics, and anti-inflammatory agents.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21333908en
dc.subject.meshAnti-Bacterial Agents-
dc.subject.meshAnti-Inflammatory Agents-
dc.subject.meshHumans-
dc.subject.meshIrritable Bowel Syndrome-
dc.subject.meshPrebiotics-
dc.subject.meshProbiotics-
dc.subject.meshSynbiotics-
dc.titleTherapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Alimentary Pharmabiotic Centre, Cork University Hospital, University College Cork, Clinical Sciences Building, Cork, Ireland. e.quigley@ucc.ieen
dc.identifier.journalGastroenterology clinics of North Americaen
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.